黄芩苷联合干扰素治疗慢性乙型肝炎50例

Baicalin combined with interferon for treating 50 patients with chronic hepatitis B

目的研究黄芩苷联合干扰素治疗慢性乙型肝炎的临床效果。方法 96例慢性乙型肝炎患者随机分为黄芩苷联合干扰素治疗组(50例)和干扰素治疗组(46例),黄芩苷联合干扰素治疗组采用黄芩苷联合干扰素α-2b治疗,干扰素治疗组仅给予干扰素α-2b,治疗6个月后观察丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、透明质酸(HA)、Ⅳ型胶原(C-Ⅳ)、层黏连蛋白(LN)以及HBV DNA和HBeAg转阴率变化。结果干扰素治疗组患者血清ALT、AST、HA、C-Ⅳ水平较治疗前下降(P<0.05,P<0.01);黄芩苷联合干扰素治疗组患者血清ALT、AST、HA、C-Ⅳ、LN水平较治疗前及干扰素治疗组治疗后均明显下降(P<0.01);黄芩苷联合干扰素治疗组HBeAg和HBV DNA转阴率均明显高于干扰素治疗组(P<0.05,P<0.01)。结论黄芩苷和干扰素联用能够抗炎、抗肝纤维化及促进HBeAg和HBVDNA转阴。

AIM To study the efficacy of baicalin combined with interferon for treating patients with chronic hepatitis B （CHB）. METHODS Ninty- six patients with CHB were randomly divided into baicalin combined with interferon alfa-2b treated group （n = 50） and interferon alfa-2b treated group （n = 46）. The serum levels of alanine aminotransferase （ALT） , aspartate aminotransferase （AST） , hyaline acid （HA） , collagen type 1V （C- IV ）, laminin （LN）, HBeAg and HBV DNA were measured before and after treatment. RESULTS After treatment, the serum levels of ALT, AST, HA and C-IV in interferon alfa-2b treated group were significantly reduced （P 〈 0.05, P 〈 0.01）. And the serum levels of ALT, AST, HA, C-IV and LN in baicalin combined with interferon alfa- 2b treated group were significantly reduced, and lower than those in interferon alfa- 2b treated group （P 〈 0.01 ）. The negative transformed rates of HBeAg and HBV DNA in baicalin combined with interferon alfa-2b treated group were significant higher than those in the interferon alfa-2b treated group （P 〈 0.05, P 〈 0.01）. CONCLUSION The combination could improve the sera negative transformed rate and protect liver cells from fibrosis. of baicalin and interferon alfa-2b inflammation and prohibitive liver